IAM1363 Shows 36% Systemic, 41% Intracranial Response Rates in Heavily Pretreated HER2 Cancers
IAM is trading near its 52-week low of $13.021 (10% above the low).
Summary
Iambic's lead asset IAM1363 posted updated Phase 1/1b data at ESMO 2026: a 36% partial response rate (19/53) systemically and 41% (9/22) intracranial in HER2-altered patients dosed at 960 mg or higher. The intracranial responses matter most — three HER2-positive breast cancer patients previously treated with both T-DXd and tucatinib achieved confirmed intracranial PRs and remain on treatment, a population with few options. Tolerability held up at the recommended 960 mg dose, with 5.9% grade 3 treatment-related events and no grade 4 or 5 TRAEs. This is the first clinical update since the company's $150 million IPO priced at $16 on October 14-15, so it is the first real test of the pipeline story for public shareholders. Parts 3 and 4 of the trial remain open to enrollment in the U.S., Europe and Asia.
At the time of this announcement, IAM was trading at $14.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $675.9M. The 52-week trading range was $13.02 to $25.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.